NEIVATECH Virtual Reality-based System for Amblyopia

NCT ID: NCT04819386

Last Updated: 2024-10-04

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

NA

Total Enrollment

20 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-07-01

Study Completion Date

2024-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The NEIVATECH system has been designed to provide binocular vision training to 7-15 year old amblyopic children by discriminating Gabor patches presented with different contrast to each eye as a perceptual learning task.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Due to the global impact of amblyopia, there is a medical and social need, and at the same time, a clear market niche, for the design and development of new therapies that can improve recurrence rates and non-compliance with conventional treatments. In this sense, the aim of this single-arm, multicentre, prospective pilot study is to examine the safety, acceptability and clinical efficacy of a novel Virtual Reality-based system designed to provide binocular vision training to 7-15 year old amblyopic children complementing the concepts of perceptual learning and dichoptic training with a gamification approach.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Amblyopia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Active group

18 half-hour in-office active vision therapy sessions with the NEIVATECH Virtual Reality-based system

Group Type EXPERIMENTAL

Active vision therapy sessions with the NEIVATECH Virtual Reality-based system

Intervention Type OTHER

The active visual therapy sessions with the NEIVATECH Virtual Reality-based system will be 18 in total, will have an average duration of half an hour and will be distributed over a month as follows: 5 sessions in the first two weeks after enrollment (Monday to Friday) and 4 sessions in the next two weeks (Monday to Thursday).

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Active vision therapy sessions with the NEIVATECH Virtual Reality-based system

The active visual therapy sessions with the NEIVATECH Virtual Reality-based system will be 18 in total, will have an average duration of half an hour and will be distributed over a month as follows: 5 sessions in the first two weeks after enrollment (Monday to Friday) and 4 sessions in the next two weeks (Monday to Thursday).

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Children aged between 7 and 15 years.
* VA in the amblyopic eye \< 0.1 logMAR units.
* Interocular difference in VA ≥ 1 logMAR line.
* Interocular difference in espherical equivalent ≥ 1 D.
* Interpupillary distance (IPD) between 60.7 and 73.5 mm.
* Use of best refractive correction for at least 2 months prior to inclusion.
* Lack of response or therapeutic adherence to conventional occlusion therapy.
* Willingness to attend all the active vision therapy sessions and/or visits of the study.
* No history of previous treatment for amblyopia other than optimal refractive correction for at least 2 months prior to inclusion.

Exclusion Criteria

* Active eye disease.
* Previous ocular surgery.
* BCVA in the amblyopic eye of ≥ 0.70 logMAR.
* Presence of cognitive impairment or neurological or psychiatric disorders.
* Presence of irregular cornea due to astigmatism or ectatic corneal disease.
Minimum Eligible Age

7 Years

Maximum Eligible Age

15 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University of Alicante

OTHER

Sponsor Role collaborator

University of Valladolid

OTHER

Sponsor Role collaborator

Hospital Clínico Universitario de Valladolid

OTHER

Sponsor Role collaborator

Increase-Tech

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Juan Francisco Arenillas Lara

Principal Investigator

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Juan Francisco Arenillas Lara, PhD

Role: PRINCIPAL_INVESTIGATOR

University of Valladolid

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University Clinical Hospital of Valladolid

Valladolid, Valladolid, Spain

Site Status

Vithas Medimar International Hospital

Alicante, , Spain

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Spain

References

Explore related publications, articles, or registry entries linked to this study.

Leal-Vega L, Coco-Martin M feminineB, Molina-Martin A, Cuadrado-Asensio R, Vallelado-Alvarez AI, Sanchez-Tocino H, Mayo-Iscar A, Hernandez-Rodriguez CJ, Arenillas Lara JF, Pinero DP. NEIVATECH pilot study: immersive virtual reality training in older amblyopic children with non-compliance or non-response to patching. Sci Rep. 2024 Nov 14;14(1):28062. doi: 10.1038/s41598-024-79565-y.

Reference Type DERIVED
PMID: 39543340 (View on PubMed)

Leal Vega L, Pinero DP, Hernandez Rodriguez CJ, Molina Martin A, Morales-Quezada L, Vallelado Alvarez AI, Arenillas Lara JF, Coco Martin MB. Study protocol for a randomized controlled trial of the NEIVATECH virtual reality system to improve visual function in children with anisometropic amblyopia. BMC Ophthalmol. 2022 Jun 7;22(1):253. doi: 10.1186/s12886-022-02466-z.

Reference Type DERIVED
PMID: 35672688 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

CASVE-NM-21-516

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Video Treatment for Amblyopia
NCT05439200 RECRUITING NA
Patch-free Occlusion Therapy
NCT05440448 RECRUITING NA